|The following article is part of conference coverage from the 2018 American Urological Association meeting in San Francisco. Renal and Urology News’ staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from AUA 2018.|
SAN FRANCISCO—Delayed rather than early initiation of targeted therapy (TT) following cytoreductive nephrectomy for metastatic renal cell carcinoma (mRCC) is not associated with worse survival, according to study findings presented at the American Urological Association 2018 annual meeting.
In a retrospective observational study that included 2716 patients with mRCC treated with both cytoreductive nephrectomy and TT, Solomon Woldu, MD, of the University of Texas Southwestern Medical Center in Dallas, and colleagues found that the risk of death among patients with moderately delayed, delayed, and late TT did not differ significantly from patients who had early TT. The investigators defined TT delivered within 2 months of mRCC diagnosis as early (1255 patients, 46.2%). They considered TT delivered in 2 to 4 months, 4 to 6 months, and more than 6 months to be moderately delayed (1072 patients, 39.5%), delayed 284 patients, 10.5%), and late (105 patients, 3.9%), respectively. The median time from mRCC diagnosis to initiation of TT was 2.1 months.
Although TT is the first-line option for mRCC, the authors noted, it is not curative and it is associated with high cost and adverse effects.
The investigators acknowledged that their study is limited by the study design and potential selection bias, but noted that the findings are consistent with the idea that, among carefully selected patients, initial observation might not compromise outcomes.
Woldu S, Matulay J, Clinton T, et al. Incidence and outcomes of delayed targeted therapy following cytoreductive nephrectomy for metastatic renal cell carcinoma: A nationwide cancer registry study. Data presented at the American Urological Association 2018 annual meeting. Abstract PD24-04.